entertainment -WSS

entertainment

author：knowledge 2025-08-23 06:50:51 - browse：2891

Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated for an average of 20 months and counting.

The attacks were reduced by an average of 98%. One patient has remained attack-free for 26 months. Two patients who suffered particularly frequent attacks, experiencing 14 and 16.8 per month, respectively, have now gone more than 20 months since their last attack.

No patient has had an attack in the last 11 months of follow-up, according to the data presented at the European Academy of Allergy and Clinical Immunology Congress. All side effects were either grade 1 or 2 on a 5-grade scale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： HHS's proposed rule does nothing to address the climate crisis

WSS

ADCs take center stage as promising cancer treatments

ADCs take center stage as promising cancer treatments

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

CZI to create biohub to build anti

Is there really a nursing shortage in the U.S.?

Welsh Carson private equity firm escapes from FTC antitrust case

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Summit: Ending the crisis of Black deaths in the U.S.

Apple is now the first public company to be valued at $3 trillion

AltruBio raises $225 million to develop ulcerative colitis drug

Trump demands the U.S. pay no more for drugs than other countries … again

STAT Summit: The economic case for universal basic health care

State Dept. review finds Biden bears some blame for Afghanistan failures

AI for drug discovery: Experts on separating hype from reality

After affirmative action ruling, medical educators look to 'holistic review'

As health system earnings go up, health insurance stocks go down

entertainment

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Why a market frenzy over new weight loss drugs defies logic

Novel spinal cord stimulator treats paralysis without surgery

Novel spinal cord stimulator treats paralysis without surgery

Empower primary care with adequate payments and technology

Merck, Daiichi strike cancer drug pact worth up to $22 billion

knowledge

hotspot

leisure time

focus